IP Library Granted Patent US 11,492,400
Granted Patent B2
US 11,492,400 · App. 16/751,951 · Granted Nov 8, 2022

Antibodies to L-type voltage gated channels and related methods

Inventors: Wilfred Arthur Jefferies (Surrey, CA); Kyung Bok Choi (Surrey, CA); Shawna Rose Stanwood (Burnaby, CA); Franz Fenninger (Vancouver, CA); Brett Alexander Eyford (Vancouver, CA); Lonna Munro (Vancouver, CA); Cheryl Gurine Pfeifer (Vancouver, CA); Reinhard Gabathuler (Quebec, CA)
Assignee: The University of British Columbia
C07K16/28C07K14/705C07K16/30C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/73C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,492,400
App. No.
16/751,951
Granted
Nov 8, 2022
Kind
B2
Abstract

Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of L-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.

Claims (1)

1. An isolated antibody, or antigen-binding fragment thereof, which binds to an alpha 1 subunit of an L-type voltage-gated calcium channel, wherein the antibody or antigen-binding fragment thereof, specifically binds to an amino acid sequence of an extracellular domain selected from SEQ ID NO:1 and which comprises a heavy chain variable region (V H ) having the V H sequence of SEQ ID NO: 13; and a light chain variable region (V L ) having the V L sequence of SEQ ID NO: 17, wherein (i) V H comprises V H CDR1, V H CDR2 and V H CDR3 amino acid sequences of SEQ ID NOS:14-16; and (ii) V L comprises V L CDR1, V L CDR2 and V L CDR3 amino acid sequences of SEQ ID NOS:18-20; wherein the antibody, or antigen-binding fragment thereof has binding specificity for Cav1.4 (SEQ ID NOS:5 and 9) and does not significantly bind to Cav1.1, Cav1.2 or Cav1.3.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2020
From: PASCAL BIOSCIENCES INC.
To: THE UNIVERSITY OF BRITISH COLUMBIA
Reel/Frame 052016/0545 →
CHANGE OF NAME Recorded Feb 7, 2020
From: BIOMMUNE TECHNOLOGIES INC.
To: PASCAL BIOSCIENCES INC.
Reel/Frame 051757/0489 →
Continuity (4)
Continuation 15549912
Provisional Application 62280557 · Jan 19, 2016
Provisional Application 62115823 · Feb 13, 2015
Related Publication 20200385458A1 · Dec 10, 2020